Diabetic Retinopathy and Ocular Melanoma: How Far We Are?

• Type: Another Publication in an International Scientific Journal
• Date: 2020

Authors

Souto, EB (Author) Other; Campos, JR (Author) Other; Da Ana, R (Author) Other; Fangueiro, JF (Author) Other; Martins Gomes, C (Author) Other; Durazzo, A (Author) Other; Lucarini, M (Author) Other; Lopez, ES (Author) Other; Espina, M (Author) Other; Garcia, ML (Author) Other; Silva, AM (Author) Other; Mendonca, F (Author) Other; Santini, A (Author) Other; Souto, SB (Author) FMUP

Journal

Title: Applied Sciences

Vol. 10

Final page: 2777

Publisher: MDPI

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00S-4WV

DOI: 10.3390/app10082777

Abstract (EN): Diabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics of chronic inflammation. The development of new therapies capable of combating vision loss involves knowledge of inflammatory retinal changes. Studies in animal models and patients with diabetes have shown a high expression of the inflammatory molecules that are involved in the progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of tumour has the ability to produce and store melanin, which may result in resistance to therapy. Over time there has been development of new therapies for this disease, such as radiotherapy and surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with angiogenesis and the current anti-angiogenic therapies for their treatment.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 27